All In Biotech

Drug Trial Radar · NCT03689244

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension

Last checked: Nov 20, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

128

Actual

Start

Jan 23, 2019

Primary completion

Jun 7, 2022

Study completion Jun 7, 2022

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in participants with inoperable or persistent/recurrent CTEPH.

Conditions

  • Chronic Thromboembolic Pulmonary Hypertension

Interventions

  • SelexipagDrug

    oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration

  • PlaceboDrug

    Oral tablets without active compound

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20Time frame: Baseline (Day 1, pre-dose), within 2 to 5 hours post-dose on Week 20

Locations

162 sites in 31 countries. Site status is shown where the registry gives one.

  • University of California San Diego Medical Center

    La Jolla, California

  • University of Southern California, Keck School of Medicine

    Los Angeles, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Colorado Springs Pulmonary Consultants

    Colorado Springs, Colorado

  • South Denver Cardiology Associates PC

    Littleton, Colorado

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago Hospitals - Chicago

    Chicago, Illinois

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • University of Maryland

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University in St. Louis

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • St. Mary's Cardiology

    Reno, Nevada

  • University of New Mexico Clinical & Translational Science Center

    Albuquerque, New Mexico

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Allegheny

    Pittsburgh, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano

    Plano, Texas

  • Intermountain Medical Center

    Murray, Utah

  • University of Utah Cardiovascular Center

    Salt Lake City, Utah

  • Medical College of Wisconsin Froedtert Hospital

    Milwaukee, Wisconsin

  • Aurora Saint Lukes Medical Center

    Milwaukee, Wisconsin

  • Sanatorio de la Trinidad Mitre

    Buenos Aires, Argentina

  • Centro Médico Dra. De Salvo

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Caba, Argentina

  • Sanatorio Ramon Cereijo

    Caba, Argentina

  • Instituto de Cardiología y Cirugía Cardiovascular - Fundación Favaloro

    Caba, Argentina

  • Hospital General de Agudos Dr Cosme Argerich

    CABA, Argentina

  • Hospital Britanico de Buenos Aires

    CABA, Argentina

  • Royal Adelaide Hospital

    Adelaide, Australia

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.